Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Next Previous
X
Search
Trial Profile

A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELA 026 (Primary) ; ELA 026 (Primary)
  • Indications Haemophagocytic lymphohistiocytosis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
  • Sponsors Electra Therapeutics

    • Most Recent Events

    • 08 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Mar 2025.
    • 08 Jul 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
    • 16 Jun 2024 According to an Electra Therapeutics media release, Phase 1b study has expanded to include up to 20 patients in Cohort 3 and will continue to evaluate ELA026 in frontline treatment settings in patients with various subtypes of sHLH. Enrollment in cohort 3 is ongoing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top